MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 565744 | Name: MM41

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MM41 is a novel bcl-2 quadruplex ligand, binding to quadruplex-forming promoter regions in a number of genes and down-regulating their transcription, showing significant in vivo anti-tumour activity against the mia paca-2 pancreatic cancer xenograft model

Chemical Structure

MM41
CAS#N/A

Theoretical Analysis

MedKoo Cat#: 565744

Name: MM41

CAS#: N/A

Chemical Formula: C44H66N10O6

Exact Mass: 830.5167

Molecular Weight: 831.08

Elemental Analysis: C, 63.59; H, 8.01; N, 16.85; O, 11.55

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
MM41; MM 41; MM-41
IUPAC/Chemical Name
4,9-Bis((3-(4-methylpiperazin-1-yl)propyl)amino)-2,7-bis(3-morpholinopropyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone
InChi Key
JOVJRDSWNCUWBX-UHFFFAOYSA-N
InChi Code
InChI=1S/C44H66N10O6/c1-47-15-19-49(20-16-47)9-3-7-45-35-31-33-38-37-34(42(56)53(43(57)39(35)37)13-5-11-51-23-27-59-28-24-51)32-36(46-8-4-10-50-21-17-48(2)18-22-50)40(38)44(58)54(41(33)55)14-6-12-52-25-29-60-30-26-52/h31-32,45-46H,3-30H2,1-2H3
SMILES Code
O=C(N(CCCN1CCOCC1)C(C2=C3C4=C(C(N5CCCN6CCOCC6)=O)C=C2NCCCN7CCN(C)CC7)=O)C3=CC(NCCCN8CCN(C)CC8)=C4C5=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 831.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ohnmacht SA, Marchetti C, Gunaratnam M, Besser RJ, Haider SM, Di Vita G, Lowe HL, Mellinas-Gomez M, Diocou S, Robson M, Šponer J, Islam B, Pedley RB, Hartley JA, Neidle S. A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer. Sci Rep. 2015 Jun 16;5:11385. doi: 10.1038/srep11385. PubMed PMID: 26077929; PubMed Central PMCID: PMC4468576. 2: Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peçzkowska M, Szmigielski C, Eng C; Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002 May 9;346(19):1459-66. PubMed PMID: 12000816. 3: Massicotte P, Snyder T, Stulak J, Baumann Kreuziger L. Ventricular assist device thrombosis: Mind your P's &Q's-Pumps, patients, and pills. J Thorac Cardiovasc Surg. 2017 Jun;153(6):1503-1506. doi: 10.1016/j.jtcvs.2016.09.092. Epub 2016 Nov 22. PubMed PMID: 27964986. 4: Raffini L, Massicotte MP. Finding the sweet spot: Titrating unfractionated heparin in children after cardiac surgery to prevent thrombosis and minimize bleeding. J Thorac Cardiovasc Surg. 2018 Jul;156(1):353-354. doi: 10.1016/j.jtcvs.2018.03.043. Epub 2018 Mar 17. PubMed PMID: 29655541. 5: Neumann HP, Bender BU. Genotype-phenotype correlations in von Hippel-Lindau disease. J Intern Med. 1998 Jun;243(6):541-5. Review. PubMed PMID: 9681856. 6: Massicotte MP, Bauman ME. Commentary: Points to ponder-Perioperative antithrombotic therapy in neonates with congenital heart disease…more harm than good? J Thorac Cardiovasc Surg. 2019 Jun;157(6):2414-2415. doi: 10.1016/j.jtcvs.2019.02.066. Epub 2019 Mar 1. PubMed PMID: 30902467. 7: Pavenstädt H. Roles of the podocyte in glomerular function. Am J Physiol Renal Physiol. 2000 Feb;278(2):F173-9. Review. PubMed PMID: 10662721. 8: Neumann HP, Hoegerle S, Manz T, Brenner K, Iliopoulos O. How many pathways to pheochromocytoma? Semin Nephrol. 2002 Mar;22(2):89-99. Review. PubMed PMID: 11891502. 9: Hymes KB, Schuck MP, Karpatkin S. Regulation of autoimmune anti-platelet antibody-mediated adhesion of monocytes to platelet GPIIb/GPIIIa: effect of armed monocytes and the Mac-1 receptor. Blood. 1990 May 1;75(9):1813-9. PubMed PMID: 2184903. 10: Pavenstädt H, Bek M. Podocyte electrophysiology, in vivo and in vitro. Microsc Res Tech. 2002 May 15;57(4):224-7. Review. PubMed PMID: 12012388. 11: Neumann HP, Cybulla M, Shibata H, Oya M, Naruse M, Higashihara E, Terachi T, Ling H, Takami H, Shuin T, Murai M. New genetic causes of pheochromocytoma: current concepts and the clinical relevance. Keio J Med. 2005 Mar;54(1):15-21. Review. PubMed PMID: 15832076. 12: Neumann HP, Riegler P, Huber W, Corradini R, Sessa A, Fontana D, Wetterauer U, Janetschek G. The challenge of kidney lesions in von Hippel-Lindau disease. Contrib Nephrol. 2001;(136):193-207. Review. PubMed PMID: 11688380. 13: Neumann HP, Bender BU, Schultze-Seemann W, Krause T, Altehoefer C, Scheremet R, Orszagh M, Schwarzkopf G, Januszewicz A, Janetschek G, Riegler P. The kidney and von Hippel-Lindau disease: impact of molecular genetic analysis of the VHL gene for clinical management. Contrib Nephrol. 1997;122:102-8. Review. PubMed PMID: 9399049. 14: Breitenfeldt MK, Gloy J, Grotz W. [Cholesterol embolism syndrome--a diagnostic challenge and a therapeutic dilemma]. Dtsch Med Wochenschr. 2000 Jul 28;125(30):909-11. German. PubMed PMID: 10962975. 15: Krumme B, Blum U. Imaging of renal artery stenosis. Curr Opin Urol. 1998 Mar;8(2):77-82. PubMed PMID: 17035846. 16: Krumme B, Pisarski P, Blum U, Kirste G, Schollmeyer P. Unusual cause of early graft dysfunction after kidney transplantation. Am J Nephrol. 1998;18(3):237-9. PubMed PMID: 9627041. 17: Krumme B, Blum U, Schwertfeger E, Flügel P, Höllstin F, Schollmeyer P, Rump LC. Diagnosis of renovascular disease by intra- and extrarenal Doppler scanning. Kidney Int. 1996 Oct;50(4):1288-92. PubMed PMID: 8887290. 18: Neumann HP, Reincke M, Bender BU, Elsner R, Janetschek G. Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. J Clin Endocrinol Metab. 1999 Aug;84(8):2608-10. PubMed PMID: 10443647. 19: Donauer J, Kölblin D, Bek M, Krause A, Böhler J. Ultrafiltration profiling and measurement of relative blood volume as strategies to reduce hemodialysis-related side effects. Am J Kidney Dis. 2000 Jul;36(1):115-23. PubMed PMID: 10873880. 20: Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump LC. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001 Jul;12(7):1530-7. PubMed PMID: 11423583.